Processa resets date for shareholder meeting

Processa Pharmaceuticals, Inc. filed an update on its shareholder meeting logistics.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. filed an update on its shareholder meeting logistics. The company convened a Special Shareholder Meeting on September 2, 2025, in Pasadena, California, but adjourned it and initially planned to reconvene on September 12, 2025, in Vero Beach, Florida. It now plans to reconvene the meeting on September 11, 2025, at 10:30 a.m. ET at its corporate office in Vero Beach, Florida.

The record date for the meeting remains August 7, 2025, meaning only stockholders of record at the close of business on that date may vote at the reconvened meeting. Stockholders who already submitted proxies or voted and do not wish to change their vote are not required to take any further action. The proposals for the meeting are unchanged, and related proxy materials remain available through the SEC’s website.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Processa Pharmaceuticals (PCSA) reconvene its shareholder meeting?

The shareholder meeting will be reconvened on September 11, 2025, at 10:30 a.m. ET at Processa Pharmaceuticals’ corporate office in Vero Beach, Florida.

What is the record date for voting at Processa Pharmaceuticals (PCSA) reconvened meeting?

The record date remains unchanged. Only stockholders of record at the close of business on August 7, 2025 are entitled to vote at the reconvened meeting.

Do Processa Pharmaceuticals (PCSA) stockholders need to resubmit their proxies?

Stockholders who have already submitted a proxy or otherwise voted and do not wish to change their vote do not need to take any additional action.

Did Processa Pharmaceuticals (PCSA) change the proposals for the shareholder meeting?

No. The company states that the proposals for the meeting remain unchanged from those described in the existing proxy materials.

Where can investors find the proxy statement and related materials for Processa Pharmaceuticals (PCSA)?

The proxy statement and other related SEC filings are available on the SEC’s website at www.sec.gov.

Why was the Processa Pharmaceuticals (PCSA) meeting adjourned and moved?

The filing states that the Special Shareholder Meeting convened on September 2, 2025, in Pasadena, California, was adjourned and rescheduled, with the reconvened meeting now set for September 11, 2025 in Vero Beach, Florida. No further reasons are described in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 10:42 AM EDT Learn about SEC filing dates

false 0001533743 0001533743 2025-09-10 2025-09-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 10, 2025

Commission file number 001-39531

PROCESSA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		45-1539785
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

601 21st Street, Suite 300, Vero Beach, FL 32960

(Address of Principal Executive Offices, Including Zip Code)

(772) 453-2899

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock: Par value $.0001		PCSA		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders

On September 2, 2025 Processa Pharmaceuticals, Inc. convened its Special Shareholder Meeting at 1:00 PM ET in Pasadena, CA.

The meeting, which was adjourned until September 12, 2025, at 5:00 PM in Vero Beach, FL will now be reconvened on September 11, 2025 at 10:30 AM ET at the corporate office in Vero Beach, FL.

The Company will not change the record date of the Annual Meeting. Accordingly, only stockholders of record at the close of business on August 7, 2025, will be entitled to vote at the reconvened Annual Meeting.

Stockholders who have previously submitted their proxy or otherwise voted and who do not wish to change their vote do not need to take any action. The proposals for the meeting remain unchanged, and the proxy statement and other SEC filings are available on the SEC’s website at www.sec.gov.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on September 10, 2025.

	PROCESSA PHARMACEUTICALS, INC.
	Registrant
	By:	/s/ George Ng
		George Ng
		Chief Executive Officer